Gender-dependent association of diabetes mellitus with mortality in patients undergoing transcatheter aortic valve replacement

• DOI: 10.1007/s00392-018-1309-0
• Publication Date: 2018-06-25T10:32:28Z
• Authors: Axel Linke; Florian Schlotter; Stephan Haussig; Felix J. Woitek; Georg Stachel; Jennifer Adam; Robert Höllriegel; Anna Lindner; Friedrich W. Mohr; Gerhard Schuler; Philipp Kiefer; Sergey Leontyev; Holger Thiele; Michael A. Borger; David Holzhey; Norman Mangner
• Keywords: Aged, 80 and over; Male; Time Factors; Aortic Valve Stenosis; Prognosis; Risk Assessment; 3. Good health; Survival Rate; Transcatheter Aortic Valve Replacement; 03 medical and health sciences; Sex Factors; 0302 clinical medicine; Risk Factors; Cause of Death; Germany; Diabetes Mellitus; Humans; Female; Sex Distribution; Aged; Follow-Up Studies; Retrospective Studies

Diabetes mellitus (DM) is a risk factor for cardiovascular disease. However, its effect on procedural and follow-up performance after transcatheter aortic valve replacement (TAVR) remains controversial.We performed an observational study of all consecutive patients treated with a transfemoral TAVR in a single-center cohort (n = 1818). All patients were stratified by diabetes status and gender. All-cause 3-year mortality was the primary endpoint. Male patients with DM were identified to have substantially increased 3-year mortality [125/314 (39.8%)] compared to males without DM [142/478 (29.7%), p < 0.01]. Male patients with DM had significantly higher 3-year mortality in comparison to female patients with (p < 0.01) or without DM (p < 0.01). There was no difference in 3-year mortality for female patients with [135/465 (29.0%)] and without DM [151/554 (27.3%); p = 0.70]. This increase in mortality in male DM patients was triggered by both cardiovascular and non-cardiovascular mortality. Furthermore, DM served as an independent predictor of 3-year mortality after TAVR selectively only in men. The interaction between male gender and diabetes mellitus was identified as an independent predictor of 3-year mortality [HR 1.88 (1.25; 2.82); p < 0.01]. DM did not affect 30-day mortality for the overall cohort and for males.Males with DM are a high-risk subgroup of patients after TAVR and require close medical attention including aggressive therapy of modifiable risk factors. Intensified diabetes management may improve long-term survival after TAVR.